{"id":"NCT00653523","sponsor":"Organon and Co","briefTitle":"Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)","officialTitle":"Open-label, Long-term Study of Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12-01","primaryCompletion":"2009-06-01","completion":"2009-06-01","firstPosted":"2008-04-07","resultsPosted":"2010-06-30","lastUpdate":"2024-05-21"},"enrollment":151,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Ezetimibe","otherNames":["SCH 58235"]},{"type":"DRUG","name":"Simvastatin","otherNames":[]}],"arms":[{"label":"Ezetimibe + Simvastatin","type":"EXPERIMENTAL"}],"summary":"Evaluate the safety of the long-term (1 year) coadministration of ezetimibe and simvastatin in patients with hypercholesterolemia who have not reached low density lipoprotein (LDL)-cholesterol target with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.","primaryOutcome":{"measure":"Number of Participants With Adverse Events and Adverse Reactions","timeFrame":"Throughout 1 year of study","effectByArm":[{"arm":"Ezetimibe + Simvastatin","deltaMin":143,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":151},"commonTop":["NASOPHARYNGITIS","C-REACTIVE PROTEIN INCREASED","BLOOD CREATINE PHOSPHOKINASE INCREASED","ALANINE AMINOTRANSFERASE INCREASED","MYOGLOBIN BLOOD INCREASED"]}}